GPT and type 2 diabetes mellitus: Conversely, in patients with T2DM (n=40) who switched from dulaglutide to tirzepatide, reductions in body weight, HbA1c, ALT, and AST were observed six months post-switch; however, no significant change in FIB-4 (baseline mean: 1.49) was reported [14].